Metformin lowers blood sugar, reduces cardiovascular risk, supports modest weight loss, and may protect against certain cancers. It’s been the most widely prescribed diabetes medication in the world for decades, and its benefits extend well beyond glucose control. Here’s what the evidence actually shows.
Blood Sugar Control
Metformin’s primary job is lowering blood sugar, and it does this well. In clinical trials, metformin monotherapy reduces HbA1c (a measure of average blood sugar over three months) by about 1.12% compared to placebo. That may sound small, but in diabetes management, a full percentage point drop in HbA1c translates to meaningfully lower risk of complications like nerve damage, kidney disease, and vision loss.
The drug works mainly by dialing down glucose production in the liver. Your liver normally releases stored sugar into the bloodstream between meals, but in type 2 diabetes, this process goes into overdrive. Metformin activates a cellular energy sensor that tells liver cells to slow that production. It also helps your muscles and other tissues absorb sugar from the blood more efficiently. Unlike some diabetes medications, metformin achieves this without pushing your pancreas to produce more insulin, which is one reason it rarely causes dangerously low blood sugar on its own.
Cardiovascular Protection
Heart disease is the leading cause of death for people with type 2 diabetes, which makes metformin’s cardiovascular benefits particularly important. A large meta-analysis pooling data from over one million patients found that metformin use was associated with a 19% lower risk of cardiovascular death and a 17% lower risk of cardiovascular events like heart attacks and strokes. The reduction in death from all causes was even more striking: 33% lower compared to patients not taking metformin.
These benefits held up across subgroups. Among patients who had already experienced a heart attack, metformin was linked to a 21% reduction in death from any cause. In patients with heart failure, a condition where metformin was once considered unsafe, it was associated with a 16% reduction in mortality. These numbers are large enough that cardiovascular protection is now considered a core reason to prescribe metformin, not just a side benefit.
Weight Management
Most diabetes medications either cause weight gain or are weight-neutral. Metformin is one of the few that nudges the scale in the other direction. The weight loss is modest but consistent: clinical trials show losses ranging from about 2 to 4 kilograms (roughly 4 to 9 pounds) over periods of six months to four years. One study of non-diabetic obese patients found an average loss of about 13 pounds over 28 weeks.
Adherence matters a lot. Patients who took their medication consistently saw an average 3.5% reduction in body weight over two years, while those with poor adherence saw essentially no change. Metformin isn’t a weight loss drug in the way newer medications like semaglutide are, but for people with type 2 diabetes who are already struggling with weight, it’s a meaningful advantage over alternatives that promote weight gain.
Benefits for PCOS
Polycystic ovary syndrome (PCOS) is one of the most common hormonal disorders in women of reproductive age, and insulin resistance is a major driver of its symptoms. Metformin has become a standard part of PCOS treatment because it targets that underlying insulin resistance rather than just masking symptoms.
By improving how the body responds to insulin, metformin helps lower the excess androgen (male hormone) levels that cause acne, unwanted hair growth, and irregular periods. Multiple studies show it restores regular menstrual cycles and triggers ovulation, either on its own or combined with fertility medications like clomifene. For women with PCOS who are trying to conceive, metformin can improve fertility by addressing the hormonal imbalance that prevents eggs from being released normally.
Lower Cancer Incidence
One of the more surprising findings about metformin is its association with reduced cancer risk. A systematic review spanning hundreds of studies found that metformin users had a lower incidence of several cancer types compared to non-users. The strongest evidence exists for gastrointestinal cancers (21% risk reduction), urologic cancers (12% reduction), and blood cancers (13% reduction).
Looking at individual cancers, the data is striking for some types. Liver cancer incidence was 27% to 46% lower depending on the study design. Colorectal cancer showed reductions of 15% to 63% across different study types. Bladder cancer was 30% lower, cervical cancer 32% lower, and esophageal cancer 32% lower. Reductions were also observed for gastric, lung, ovarian, prostate, and thyroid cancers. These are associations from observational studies, not proof that metformin directly prevents cancer, but the consistency across so many cancer types and study designs is hard to ignore. Researchers believe metformin’s effect on cellular energy pathways and insulin levels may create an environment less hospitable to tumor growth.
Potential Anti-Aging Effects
Metformin has attracted serious interest as a potential anti-aging drug. The Targeting Aging with Metformin (TAME) trial, coordinated through Wake Forest University School of Medicine, is designed to test whether metformin can delay the development of age-related diseases like heart disease, cancer, and dementia in people aged 65 to 79. The trial is planned for 14 research institutions across the U.S. and would follow over 3,000 participants for six years. The study design is complete, though it still needs full funding to launch.
If successful, TAME would be the first clinical trial to establish that a drug can treat aging itself, not just individual diseases. The idea isn’t that metformin makes you live forever. It’s that by targeting the biological processes behind aging, one medication could delay the onset of multiple chronic diseases at once rather than treating each one separately.
Common Side Effects and B12 Deficiency
Metformin is generally well tolerated, but it’s worth knowing what to expect. The most common side effects are gastrointestinal: nausea, diarrhea, bloating, and stomach cramps, especially in the first few weeks. These typically improve over time, and starting at a low dose with gradual increases helps. Extended-release formulations also cause fewer stomach issues than the standard version.
A less obvious concern is vitamin B12 deficiency. One cross-sectional study found that nearly half (48.9%) of type 2 diabetes patients who had taken metformin for at least a year had B12 levels below the deficiency threshold. B12 deficiency can cause fatigue, numbness or tingling in the hands and feet, and memory problems, symptoms that can easily be mistaken for diabetic neuropathy. If you take metformin long-term, periodic B12 testing is a simple precaution.
Kidney Function Thresholds
Metformin was historically considered off-limits for anyone with kidney problems because of a rare but serious complication called lactic acidosis. Guidelines have loosened considerably as evidence has accumulated. Metformin is considered safe when kidney filtration rate (eGFR) is 45 or above. Between 30 and 44, doctors generally won’t start it fresh, but patients already taking it can continue at a reduced dose. Below 30, it’s contraindicated. Your kidney function is checked with a routine blood test, and your doctor will monitor it periodically if you’re on metformin.